KLAR — Klaria Pharma Holding AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK234.17m
- SEK233.83m
- SEK8.99m
Annual income statement for Klaria Pharma Holding AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 5.87 | 8.45 | 2.25 | 8.98 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 50.1 | 60.8 | 40.3 | 33.5 | 34.2 |
| Operating Profit | -50.1 | -55 | -31.8 | -31.2 | -25.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -53.5 | -63.7 | -35.8 | -47.7 | -38.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -53.5 | -63.8 | -35.8 | -47.8 | -38.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -53.5 | -63.8 | -35.8 | -47.8 | -38.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -53.5 | -63.8 | -35.8 | -47.8 | -38.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.944 | -1 | -0.346 | -0.349 | -0.206 |
| Dividends per Share |